The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are usually associated with loss of dopaminergic neurons. Loss of substantia nigra neurons and presence of Lewy body inclusions in some of the remaining neurons are the hallmark pathology seen in the final stages of the disease. Attempts to correlate Lewy body pathology to either cell death or severity of clinical symptoms, however, have not been successful. While the pathophysiology of the neurodegenerative process can hardly be explained by Lewy bodies, the clinical symptoms do indicate a degenerative process located at the presynapse resulting in a neurotransmitter deficiency. Recently it was shown that 90% or even more of alpha-synuclein aggregates in DLB cases were located at the presynapses in the form of very small deposits. In parallel, dendritic spines are retracted, whereas the presynapses are relatively preserved, suggesting a neurotransmitter deprivation. The same alpha-synuclein pathology can be demonstrated for PD. These findings give rise to the notion that not cell death but rather alpha-synuclein aggregate-related synaptic dysfunction causes the neurodegeneration. This opens new perspectives for understanding PD and DLB. If presynaptic alpha-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future. The disease may progress via trans-synaptical spread, suggesting that stem cell transplants are of limited use. Future therapies may focus on the regeneration of synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“It could be demonstrated that the presence of symptoms may be related to the involvement of defined regions as measured by the occurrence of Lewy bodies [47–49], supporting the observations that the a-synuclein aggregation pathology spreads through the brain involving anatomical structures sequentially [13].”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The discovery of mutations in the a-synuclein gene [77, 114, 156] and overexpression of a-synuclein [123] as being associated with Parkinson’s disease or dementia with Lewy bodies (DLB) strengthens the association between protein”
BackgroundParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 2×
“Tremor at rest, rigidity, akinesia/bradykinesia and postural instability are the four cardinal features in Parkinson’s disease [60].”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“association between the frequency and extension of tangles and Ab-plaques and the occurrence of the disease [55, 104], Terry et al.”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It was assumed that the cognitive impairment in AD is related to a synaptic failure [121, 124, 130].”
Background
Cited by
Items 401–500 of 664
Kruse, N., Schlossmacher, M. G., Schulz‐Schaeffer, W., Vanmechelen, E., Vanderstichele, H., El‐Agnaf, O. M. A., & Mollenhauer, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153564 · Cited by 12
Self-citationKrishna, S., Prasad, S., Goel, R. K., & Prasad, B. K. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/295 · Cited by 10
What autoantibodies tell us about the pathogenesis of Parkinson's disease
Bach, J., & Falkenburger, B. H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14340 · Cited by 10
“This finding is consistent with the presumed association between a-synuclein pathology and cognitive impairment (Schulz-Schaeffer 2010), and with the view that a-synuclein autoantibodies in PD reflect the extent of pathology.”
ResultNeuroanatomical correlates of polygenic risk for Parkinson’s DiseasePreprint
Abbasi, N., Tremblay, C., Rajimehr, R., Yu, E., Markello, R. D., Shafiei, G., Khatibi, N., study, T. E.-P., Jahanshad, N., Thompson, P. M., et al. (2022) · medRxiv · doi:10.1101/2022.01.17.22269262 · Cited by 10
Global network and local vulnerabilities underlie brain atrophy across Parkinson’s disease stages
Vo, A., Tremblay, C., Rahayel, S., Al–Bachari, S., Berendse, H. W., Bright, J. K., Cendes, F., d’Angremont, E., Dalrymple‐Alford, J. C., Debove, I., et al. (2025) · Brain · doi:10.1093/brain/awaf432 · Cited by 9
“94-96 This loss of neuropil;the synapses, axons, and dendrites within cortical columns;would be reflected in cortical thinning.”
Striato-cortical functional connectivity changes in mild cognitive impairment with Lewy bodies
Novakova, L., Gajdoš, M., Bartoň, M., Brabenec, L., Železníková, Ž., Morávková, I., & Rektorová, I. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106031 · Cited by 10
Alpha‐Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction
Ponterio, G., Faustini, G., Atiallah, I. E., Sciamanna, G., Meringolo, M., Tassone, A., Imbriani, P., Cerri, S., Martella, G., Bonsi, P., et al. (2022) · Movement Disorders · doi:10.1002/mds.29024 · Cited by 9
Nižetić, D., Chen, C., Hong, W., & Koo, E. H. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00299 · Cited by 10
“However, some cardiovascular risk factors, including hypertension, atherosclerosis, and smoking (McGowan et al., 2006; Troca-Marín et al., 2012) that are thought to contribute to the development of dementia in the general population (Schulz-Schaeffer, 2010), are lower among adults with DS.”
BackgroundInvolvement of ubiquilin-1 transcript variants in protein degradation and accumulation
Haapasalo, A., Viswanathan, J., Kurkinen, K. M. A., Bertram, L., Soininen, H. S., Dantuma, N. P., Tanzi, R. E., & Hiltunen, M. O. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.15283 · Cited by 9
Targeting Neurodegeneration: The Emerging Role of Hybrid Drugs
Deb, D., Dhanawat, M., Bhushan, B., Pachuau, L., & Das, N. (2025) · Current Drug Targets · doi:10.2174/0113894501365588250131073304 · Cited by 9
Casiraghi, A., Longhena, F., Faustini, G., Ribaudo, G., Suigo, L., Camacho‐Hernandez, G. A., Bono, F., Brembati, V., Newman, A. H., Gianoncelli, A., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081595 · Cited by 8
Comparative mapping of single‐cell transcriptomic landscapes in neurodegenerative diseases
Shwab, E. K., Man, Z., Gingerich, D. C., Gamache, J., Garrett, M. E., Serrano, G. E., Beach, T. G., Crawford, G. E., Ashley‐Koch, A. E., & Chiba‐Falek, O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70012 · Cited by 8
“…cortical neurotransmitter dysregulation and synaptic dysfunction likely play a central role in cognitive impairment in both PD 71–74 and DLB. 75,76 Consistently, we found that disease-driving neurons for DLB and PD were primarily excitatory subtypes, and the enriched GWAS genes showing…”
Lakatos, A., Goldberg, N. R. S., & Blurton-Jones, M. M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0421-0 · Cited by 8
Ekmark‐Lewén, S., Aniszewska, A., Molisak, A., Gumucio, A., Lindström, V., Kahle, P. J., Nordström, E., Möller, C., Fälting, J. M., Lannfelt, L., et al. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100086 · Cited by 9
“Whereas Lewy bodies were previously believed to be the only disease-causing pathological entity [5], both ex vivo and in vivo studies have indicated that soluble α-syn oligomers and protofibrils are more prone to exert toxic effects, such as disruption of cellular membranes [6,7] and inflammatory reactions [8,9].”
BackgroundPatwekar, M., Patwekar, F., Sanaullah, S., Shaikh, D., Almas, U., & Sharma, R. (2023) · Trends in Immunotherapy · doi:10.24294/ti.v7.i2.2395 · Cited by 10
“…α-syn and dopamine, nigrostriatal pathway synapses are most likely to be main site of the formation of hazardous adducted of α-syn and oxidized DA [51–53] furthermore, faulty mitochondria respiration, turnover, or axonal transport may affect the energy requirements of synapses [54] locally…”
BackgroundExploring the potential of MFG-E8 in neurodegenerative diseases
Li, D., Wang, R., Lu, W., & Ma, Y. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2417800 · Cited by 11
“It may exert protective effects by promoting autophagy (Kohl et al. 2012; Schulz-Schaeffer 2010).”
Martínez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.006 · Cited by 8
Alzheimer's Disease and Other Neurodegenerative Diseases
Fuller, S. J., Sohrabi, H. R., Goozee, K. G., Sankaranarayanan, A., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch2 · Cited by 8
Proteomic Characterization of the Olfactory Molecular Imbalance in Dementia with Lewy Bodies
Lachén‐Montes, M., Mendizuri, N., Schvartz, D., Fernández‐Irigoyen, J., Sánchez, J. C., & Santamaría, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176371 · Cited by 8
Huang, K., Tang, X., Li, Y., Zhang, Z., Ye, K. X., Shen, Q.-F., Wang, X., Zhu, X., Huang, X., Lu, G., et al. (2020) · Aging · doi:10.18632/aging.103674 · Cited by 8
Neuropathological substrates of cognition in Parkinson's disease
Coughlin, D. G., & Irwin, D. J. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.014 · Cited by 8
Wang, Z., Xu, Z., Luo, Y., Peng, S., Song, H., Li, T., Zheng, J., Liu, N., Wu, S., Zhang, J., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1208274 · Cited by 7
“Synaptic dysfunction is a common pathological feature in complex neurological diseases (Galvin et al., 1999; Milnerwood and Raymond, 2010; Schulz-Schaeffer, 2010; Lu et al., 2013).”
BackgroundKhodadadi, M., & Javadi, B. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575306884240604065754 · Cited by 7
Serra, M., Faustini, G., Brembati, V., Casu, M. A., Pizzi, M., Morelli, M., Pinna, A., & Bellucci, A. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115040 · Cited by 10
Román‐Vendrell, C., Wallace, J. N., Watson, A. H., Celikag, M., Bartels, T., & Morgan, J. R. (2024) · The Journal of Physiology · doi:10.1113/jp286281 · Cited by 8
Dayan, E., & Sklerov, M. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00014-9 · Cited by 7
Sensi, S. L., Russo, M., & Tiraboschi, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00015-8 · Cited by 7
Sargent, D., Bétemps, D., Drouyer, M., Verchère, J., Gaillard, D., Arsac, J.-N., Lakhdar, L., Salvetti, A., & Baron, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-35825-2 · Cited by 7
Protein trapping leads to altered synaptic proteostasis in synucleinopathies
Santos, P. I., & Outeiro, T. F. (2020) · FEBS Journal · doi:10.1111/febs.15364 · Cited by 7
Lewy Body Dementias: Controversies and Drug Development
Chiu, S., Bowers, D., & Armstrong, M. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01161-z · Cited by 7
Beekes, M. (2021) · Viruses · doi:10.3390/v13071394 · Cited by 7
CSF α-synuclein, tau, and amyloid β in Parkinson's disease – Authors' reply
Mollenhauer, B., Schulz‐Schaeffer, W., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70161-2 · Cited by 7
Self-citationA novel approach to detecting plasma synuclein aggregates for Parkinson’s disease diagnosis
Ko, H. R., Lee, D., Park, H., Jeong, H., Yoon, T., Kang, S., Park, H. L., Kwon, S. J., Kim, S., Ryoo, N., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01083-z · Cited by 7
The dysregulated Pink1- Drosophila mitochondrial proteome is partially corrected with exercise
Ebanks, B., Ingram, T. L., Katyal, G., Ingram, J. R., Moisoi, N., & Chakrabarti, L. (2021) · Aging · doi:10.18632/aging.203128 · Cited by 6
“Molecular characteristics of PD include the aggregation of α-synuclein leading to Lewy body formation, alongside mitochondrial dysfunction(Schulz-Schaeffer, 2010; Park et al, 2018).”
BackgroundНовиков, Н. Ю., Brazhnik, E. S., & Кичигина, В. Ф. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523110180 · Cited by 7
Radulovic, J., Ivković, S., & Adžić, M. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00025-4 · Cited by 7
Neuropathology of Parkinson's Disease: An Update of the Recent Findings
El‐Mansoury, B., Hiba, O. E., Agnaou, M., Jayakumar, A. R., Khiat, A. E., Kahim, K., Boulbaroud, S., Zouhairi, N., Tibssirte, O., Bouighajd, H., et al. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5156-4.ch006 · Cited by 7
Safinamide: A Novel anti-Parkinsonian Drug With Multiple Actions
Borgohain, R., & Kandadai, R. M. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.17 · Cited by 6
Zhou, H., Jiang, J., Wu, P., Guo, Q., & Zuo, C. (2018) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8512637 · Cited by 8
“small-world property might be associated with the presynaptic dysfunction caused by α -synuclein aggregates which are present in the brain cortex, even at early stages of the disease [10, 11].”
BackgroundGenetic Variation in Complex Traits in Transgenic α-Synuclein Strains of Caenorhabditis elegans
Wang, Y. A., van Sluijs, L., Nie, Y., Sterken, M. G., Harvey, S. C., & Kammenga, J. E. (2020) · Genes · doi:10.3390/genes11070778 · Cited by 8
Moreno‐Valladares, M., Moncho-Amor, V., Simón, I. B., Agirre, E., Álvarez‐Satta, M., & Matheu, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158376 · Cited by 6
Associations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease
Oizumi, H., Hasegawa, T., Kawahata, K., Sekimori, T., Totsune, T., Sugimura, Y., Baba, T., Fukunaga, K., & Takeda, A. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100313 · Cited by 5
“Then, Lewy bodies (LBs) are formed in the soma [20 – 22].”
Astrocyte alterations in α-synucleinopathies
Rodríguez-Castañeda, M., Campos-Ríos, A., Lamas, J. A., & Covelo, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1650326 · Cited by 5
Neural networks reveal novel gene signatures in Parkinson disease from single-nuclei transcriptomes
Fiorini, M. R., Li, J., Fon, E. A., Farhan, S. M. K., & Thomas, R. A. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01147-0 · Cited by 9
“The LIME optimalgenesetforneuronswasenrichedforgenesinvolvedinaggrephagy, whiletheDaNeurongenesetwasenrichedfortermssuggestingsynaptic dysfunction,whichhasbeenlinkedtothelossofthisvulnerablecelltype inPD 24 .”
Xu, Y., Denkinger, M. N., Liu, M., Gong, K., Chen, Y., Western, D., Timsina, J., Cheng, Y., Xie, Y., Mu, R., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71420 · Cited by 5
RECENT TRENDS IN TREATING NEURONAL PROTEINOPATHIES
Chowhan, R. K., Warepam, M., Dar, T. A., & Singh, L. R. (2013) · Journal of Proteins and Proteomics · Cited by 7
Marmosets in Neurologic Disease Research
Philippens, I. H. C. H. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811829-0.00023-6 · Cited by 6
Re-examining the pathobiological basis of gait dysfunction in Parkinson’s disease
Cho, N., Kalia, L. V., & Kalia, S. K. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.01.002 · Cited by 6
Yeast as a Model System to Study Human Diseases
Poswal, A. M., & Saini, A. K. (2017) · Springer eBooks · doi:10.1007/978-981-10-5511-9_10 · Cited by 6
Lelos, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00002-7 · Cited by 5
Rho‐kinase inhibition by fasudil modulates pre‐synaptic vesicle dynamics
Saal, K. A., Arias, C. C. W. P., Roser, A., Koch, J. C., Bähr, M., Rizzoli, S. O., & Lingor, P. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15274 · Cited by 6
“Synaptic dysfunction is known to play a critical role in numerous neurodegenerative pathologies (Schulz-Schaeffer, 2010; Spronsen & Hoogenraad, 2010; Wishart et al., 2006), and is an early event, predating the loss of neuronal projections.”
BackgroundYang, X., Shi, H., Zhao, H., Zhang, S., Yan, C., Zu, J., Zhang, W. Y., Shen, X., Cun, G., & Hua, F. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s80174 · Cited by 5
“Introduction Parkinson’s disease (PD) is a kind of neurodegenerative disease, which is characterized by loss of dopaminergic neurons in the substantia nigra.(1) Levodopa (l-dopa) remains the best drug in the treatment of PD.”
Neurobiology of Non-Motor Symptoms in Parkinson Disease
Jellinger, K. A. (2014) · Cited by 5
Banks, S. M. L., Morgan, J. R., Medeiros, A. T., Sousa, R., & Lafer, E. M. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.300431 · Cited by 5
Gouras, G. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00159-8 · Cited by 5
Magnetic Resonance Spectroscopy in the Diagnosis of Dementia with Lewy Bodies
Magierski, R., & Sobów, T. (2014) · BioMed Research International · doi:10.1155/2014/809503 · Cited by 5
Small molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook
Hajam, I. B., Ahanger, I. A., Rasool, U., & Dar, T. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.017 · Cited by 5
Kumar, M., & Feldman, R. A. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf166 · Cited by 4
“The hallmark of PD and LBD is the presence of α -synuclein aggregates that accumulate in Lewy bodies [82].”
Benussi, A., & Vucic, S. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2025.2111459 · Cited by 5
Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer’s disease
Lan, G., Li, B., Wang, M., Barve, A., Colin, M., Buée, L., Zhang, L., Jiang, M., Yang, J., Li, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102508 · Cited by 4
“5,8,12 16 Nevertheless, blood levels of common synaptic proteins, such as neurogranin 17 and synapto-some-associated protein 25 (SNAP-25), 18 have not been corroborated as reliable indicators of brain pathology due to peripheral confounds and detection limits.”
Targeting PI3K/Akt/mTOR with fisetin mechanistic and therapeutics insights for Parkinson’s disease
Barik, S. K., Bansal, R., & Singh, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100319 · Cited by 4
Dopamine and Rotenone Modulate α‐Synuclein Phase Separation and Liquid to Solid Transition
Bera, R., Manna, S., Shaw, R., Bhattacharyya, A., & Maji, S. K. (2026) · Small · doi:10.1002/smll.202514922 · Cited by 4
Distinctive characteristics of dopamine neuron release mechanisms: Insights into Parkinson’s Disease
Martino, E. D., Maduro, S., Luchicchi, A., Wilhelmus, M. M. M., & Orefice, N. S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119534 · Cited by 4
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
A New Interpretative Paradigm for Conformational Protein Diseases
Agnati, L. F., Guidolin, D., Woods, A. S., Ciruela, F., Carone, C., Vallelunga, A., Escuela, D. O. B., Genedani, S., & Fuxé, K. (2013) · Current Protein and Peptide Science · doi:10.2174/1389203711314020006 · Cited by 5
The Aging Brain: From Physiology to Neurodegeneration
Rajput, R., Kaur, R., Chadha, R., Mani, S., Rachana, R., Kaur, H., & Singh, M. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch001 · Cited by 4
Dementia with Lewy bodies – a clinicopathological update
Bencze, J., Seo, W., Hye, A., Aarsland, D., & Hortobágyi, T. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2613 · Cited by 4
Regional Brain Stiffness Analysis of Dementia with Lewy Bodies
Pavuluri, K., Huston, J., Ehman, R. L., Manduca, A., Jack, C. R., Savica, R., Boeve, B. F., Kantarci, K., Petersen, R. C., & Murphy, M. C. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27970 · Cited by 4
Jia, B., Zhao, Y., Ren, X., Zhang, D., Jia, H., Wang, L., Wang, L., & Li, J. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106036 · Cited by 3
Marsal-García, L., Mena, J., Lao, C., Adamuz, D., Arnaldo, L., Carrato, C., Albarracín, A. M., Samaniego, D., Vilas, D., Ispierto, L., et al. (2025) · Brain Pathology · doi:10.1111/bpa.70059 · Cited by 4
“Lewy bodies (LB), consisting mainly of abnormally folded aggregated alpha-synuclein (AS), are the neuro-pathological hallmark of LB disorders, which include dementia with Lewy bodies (DLB) and Parkinson ’ s disease (PD) [1, 2].”
α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives
Grimwade, I. J., Enticknap, G., Pablo‐Fernández, E. D., & Croft, C. L. (2026) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2026.10037 · Cited by 3
Ranjan, P. (2026) · Bioscience Reports · doi:10.1042/bsr20260364 · Cited by 3
“They also impair Ca 2+ -evoked exocytosis [17].”
Woo, K. (2024) · Medical Lasers · doi:10.25289/ml.24.015 · Cited by 3
Ektirici, S., & Harmandaris, V. (2025) · Soft Matter · doi:10.1039/d4sm01395f · Cited by 3
Otero‐Jimenez, M., Wojewska, M. J., Jogaudaite, S., Miller, D. E., Gray‐Rodriguez, S., Geoghegan, G., Abelleira, L. E., Viney, T. J., Sárkány, B., Gveric, D. O., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01111-y · Cited by 3
Soliman, G. F., Hashem, G., Fawzy, M. G., & Ibrahim, W. (2019) · Egyptian Journal of Basic and Clinical Pharmacology · doi:10.32527/2019/101450 · Cited by 4
“Also, Fernandes et al. [27] stated that reserpine increased lipid peroxidation in the striatal, which represented damage of neurons by oxidative stress in addition to the presence of Lewy bodies at the substantia nigra and locus coeruleus in the pathological examination of rat brains this was in accordance with Schulz…”
ResultClinical Trial Highlights – Parkinson’s Disease Cognition
Prakash, N., McFarthing, K., & Simuni, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-209006 · Cited by 3
Zamora, C. A., Muhleman, M., & Castillo, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_31 · Cited by 4
Cuevas, E., Guzmán, A., Burks, S. M., Ramirez-Lee, A., Ali, S. F., & Imam, S. Z. (2022) · Toxicology Reports · doi:10.1016/j.toxrep.2022.03.047 · Cited by 3
Perspective on Cav-1 for its Potential as Newer Therapeutics for Parkinson’s Disease
Singh, G., Pushpa, T., Gupta, S., Srivastava, S., Khatri, D. K., & Singh, S. B. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220909150406 · Cited by 3
Theoretical Aspects of Protein Aggregation and Neurodegenerative Diseases
Singh, V. K., & Dey, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006957 · Cited by 6
Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease
Jakobsson, P., Nilsson, J., Nygren, M., Zetterberg, H., Blennow, K., Constantinescu, R., Constantinescu, J., Brinkmalm, A., & Bäckström, D. C. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123683 · Cited by 3
Todo, M. (2020) · Neuroscience Research · doi:10.1016/j.neures.2020.02.009 · Cited by 3
Asai, T. T., & Sugiyam, T. (2007) · PubMed · Cited by 4
McGill, A. (2016) · Cited by 5
Antoniou, N., Prodromidou, K., Kouroupi, G., Samiotaki, M. K., Panayotou, G., Xilouri, M., Stefanis, L., Grailhe, R., Taoufik, E., & Matsas, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.12.148031 · Cited by 3
Scheller, U., Lee, C., Seibler, P., Mitkovski, M., Rhee, J., & van Riesen, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.07.606995 · Cited by 3
Dutta, S., Hensel, J. A., Scott, A. N., Mohallem, R., Rossitto, L.-A. M., Khan, H. F., Diehl, L. A., Johnson, T., Colon, B. D., Gold, J. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634820 · Cited by 3
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
A Roadmap for Future Parkinson's Pharmacogenomics in Asia
Akbar, M., Soraya, G. V., Ulhaq, Z. S., & Bintang, A. K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896371 · Cited by 2
Differentiating α-synuclein aggregates using charge-sensitive gold nanoclusters
Kaur, H., Tyagi, A., Sharma, I., Sharma, D., & Sinha, S. (2025) · Nanoscale · doi:10.1039/d5nr00887e · Cited by 2
Kidney Impairment and α-Synucleinopathy: Implications for Assessment and Treatment
Lepkowsky, C. M. (2025) · The American Journal of Geriatric Psychiatry Open Science Education and Practice · doi:10.1016/j.osep.2025.10.001 · Cited by 2
TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson’s disease
Ahumada, P., Muñoz-Carvajal, F., Borquez, S., Arévalo-Ramírez, N., Cisternas-Olmedo, M., Jerez, C., Urbina-Muñoz, V., Gómez, W., Urrutia, P. J., Hirsch, É. C., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08391-5 · Cited by 2
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 4
Limke, A., Poschmann, G., Stühler, K., Petzsch, P., Wachtmeister, T., & von Mikecz, A. H. (2024) · Journal of Xenobiotics · doi:10.3390/jox14010008 · Cited by 2
Neuroglia targeting nano-therapeutic approaches to rescue aging and neurodegenerating brain
Sharma, M., Aggarwal, N., Mishra, J., & Panda, J. J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123950 · Cited by 3
Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets
Godde, K., Raut, S. P., Rokde, R., & Zatke, L. (2025) · Geriatric Care · doi:10.4081/gc.2025.13936 · Cited by 2
Finelli, A., & Labanti, M. (2010) · Frattura ed Integrità Strutturale · doi:10.3221/igf-esis.13.03 · Cited by 5
Morbus Parkinson – A synaptic disorder?
Schulz‐Schaeffer, W. (2014) · Basal Ganglia · doi:10.1016/j.baga.2014.03.006 · Cited by 2
Self-citationEssential Tremor—Not Just A Shake
Dalvi, A., & Mercury, M. G. (2011) · Disease-a-Month · doi:10.1016/j.disamonth.2011.02.005 · Cited by 2
Metadata
- Authors
- Schulz-Schaeffer, W. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-06-20
- Volume
- 120
- Issue
- 2
- Pages
- 131-143
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2892607
- OpenAlex
- W2033827101
- Cited by
- 627
- References
- 165
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 45 · 2023: 24 · 2022: 43 · 2021: 48 · 2020: 48 · 2019: 41 · 2018: 40 · 2017: 35 · 2016: 36 · 2015: 29 · 2014: 41 · 2013: 36 · 2012: 35
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Funders
- Volkswagen Foundation (ZN 2168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein aggregation, Lewy bodies, dementia with Lewy bodies, Parkinson's disease, Parkinson's disease dementia, presynaptic dysfunction, synaptic pathology, neurotransmitter deficiency, neurodegeneration, trans-synaptic spread, stem cell transplantation, synapse regeneration
- MeSH terms
- Animals, Brain, Parkinson Disease, Synapses, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.